David H. Salinger

1.1k total citations
25 papers, 772 citations indexed

About

David H. Salinger is a scholar working on Epidemiology, Immunology and Hematology. According to data from OpenAlex, David H. Salinger has authored 25 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 6 papers in Immunology and 5 papers in Hematology. Recurrent topics in David H. Salinger's work include Acute Lymphoblastic Leukemia research (4 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Dermatology and Skin Diseases (3 papers). David H. Salinger is often cited by papers focused on Acute Lymphoblastic Leukemia research (4 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Dermatology and Skin Diseases (3 papers). David H. Salinger collaborates with scholars based in United States, India and Canada. David H. Salinger's co-authors include James J. Anderson, Paolo Vicini, Roland Martinꝉ, Christopher J. Endres, Megan Gibbs, Jeannine S. McCune, Chris B. Russell, John P. Gibbs, Jennifer Dong and Cheng‐Pang Hsu and has published in prestigious journals such as The Journal of Immunology, Analytical Chemistry and Clinical Cancer Research.

In The Last Decade

David H. Salinger

25 papers receiving 740 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David H. Salinger United States	17	297	170	132	121	109	25	772
Öztürk Özdemir Türkiye	16	142 0.5×	284 1.7×	170 1.3×	24 0.2×	38 0.3×	102	910
A McMillan United States	13	132 0.4×	277 1.6×	68 0.5×	205 1.7×	62 0.6×	15	917
M Kashimura Japan	19	145 0.5×	246 1.4×	139 1.1×	27 0.2×	30 0.3×	71	1.2k
Alexandra M. Harrington United States	17	126 0.4×	398 2.3×	227 1.7×	33 0.3×	57 0.5×	64	1.0k
Lois La Grenade United States	12	462 1.6×	54 0.3×	108 0.8×	78 0.6×	12 0.1×	20	937
Simon Jiang Australia	14	203 0.7×	95 0.6×	21 0.2×	54 0.4×	46 0.4×	42	646
Frank Firkin Australia	19	172 0.6×	463 2.7×	418 3.2×	42 0.3×	44 0.4×	67	1.3k
Keith Sacco United States	12	194 0.7×	61 0.4×	33 0.3×	90 0.7×	13 0.1×	51	670
Robert Delage Canada	18	205 0.7×	141 0.8×	400 3.0×	11 0.1×	47 0.4×	58	957
K Grünewald Austria	15	86 0.3×	291 1.7×	224 1.7×	40 0.3×	18 0.2×	30	846

Countries citing papers authored by David H. Salinger

Since Specialization

Citations

This map shows the geographic impact of David H. Salinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Salinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Salinger more than expected).

Fields of papers citing papers by David H. Salinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Salinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Salinger. The network helps show where David H. Salinger may publish in the future.

Co-authorship network of co-authors of David H. Salinger

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Salinger. A scholar is included among the top collaborators of David H. Salinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Salinger. David H. Salinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Peter, Vidya Perera, David H. Salinger, et al.. (2024). Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration. CPT Pharmacometrics & Systems Pharmacology. 13(9). 1462–1475. 2 indexed citations

Salinger, David H., Maria Palmisano, Amy J. Sehnert, et al.. (2024). Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy. CPT Pharmacometrics & Systems Pharmacology. 13(9). 1448–1461. 2 indexed citations

Nedelman, Jerry, David H. Salinger, Vishak Subramoney, et al.. (2020). An Exposure-Response Perspective on the Clinical Dose of Pretomanid. Antimicrobial Agents and Chemotherapy. 65(1). 9 indexed citations

Li, Hanbin, David H. Salinger, Daniel E. Everitt, et al.. (2019). Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy. 63(10). 23 indexed citations

Salinger, David H., Christopher J. Endres, Roland Martinꝉ, & Megan Gibbs. (2014). A semi‐mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first‐in‐human single ascending dose study. Clinical Pharmacology in Drug Development. 3(4). 276–283. 21 indexed citations

McCune, Jeannine S., Paolo Vicini, David H. Salinger, et al.. (2014). Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemotherapy and Pharmacology. 75(1). 67–75. 12 indexed citations

Russell, Chris B., Hugh Rand, Jeannette Bigler, et al.. (2014). Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody. The Journal of Immunology. 192(8). 3828–3836. 128 indexed citations

Li, Hong, Kathleen Köck, William A. Rees, et al.. (2014). Prediction of clinical pharmacokinetics of AMG 181, a human anti‐α₄β₇ monoclonal antibody for treating inflammatory bowel diseases. Pharmacology Research & Perspectives. 3(1). e00098–e00098. 14 indexed citations

Endres, Christopher J., David H. Salinger, Kathleen Köck, et al.. (2014). Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. The Journal of Clinical Pharmacology. 54(11). 1230–1238. 21 indexed citations

10.

Easterling, Thomas R., et al.. (2012). OS034. Magnesium sulfate for prevention of eclampsia: Are intramuscularand intravenous regimens equivalent?. Pregnancy Hypertension. 2(3). 194–194. 1 indexed citations

11.

Dong, Jennifer, David H. Salinger, Christopher J. Endres, et al.. (2011). Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies. Clinical Pharmacokinetics. 50(2). 131–142. 119 indexed citations

12.

Li, Hong, Donald E. Mager, Meagan J. Bemer, et al.. (2011). A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration‐Time Curve in Hematopoietic Cell Transplantation Recipients. The Journal of Clinical Pharmacology. 52(11). 1654–1664. 17 indexed citations

13.

Salinger, David H., et al.. (2010). Development of a Population Pharmacokinetics‐Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration. The Journal of Clinical Pharmacology. 50(11). 1292–1300. 29 indexed citations

14.

Tomazela, Daniela M., Bruce W. Patterson, David H. Salinger, et al.. (2010). Measurement of Human Surfactant Protein-B Turnover in Vivo from Tracheal Aspirates Using Targeted Proteomics. Analytical Chemistry. 82(6). 2561–2567. 18 indexed citations

15.

Salinger, David H., David K. Blough, Paolo Vicini, et al.. (2009). A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. Clinical Cancer Research. 15(16). 5280–5287. 22 indexed citations

16.

Salinger, David H., Danny D. Shen, Kenneth E. Thummel, et al.. (2009). Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenetics and Genomics. 19(12). 965–971. 5 indexed citations

17.

McCune, Jeannine S., et al.. (2008). Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group. The Journal of Clinical Pharmacology. 49(1). 88–102. 39 indexed citations

18.

Lynn, Anne M, Heidi Bradford, Eric D. Kantor, et al.. (2007). Postoperative Ketorolac Tromethamine Use in Infants Aged 6–18 Months: The Effect on Morphine Usage, Safety Assessment, and Stereo-Specific Pharmacokinetics. Anesthesia & Analgesia. 104(5). 1040–1051. 27 indexed citations

19.

Salinger, David H., Jeannine S. McCune, Danny D. Shen, et al.. (2006). Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach. Clinical Cancer Research. 12(16). 4888–4898. 36 indexed citations

20.

Salinger, David H., James J. Anderson, & Owen S. Hamel. (2003). A parameter estimation routine for the vitality-based survival model. Ecological Modelling. 166(3). 287–294. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact